Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary
August 10, 2023
Earnings Call Speaker Segments
Jennifer Good
executiveGood afternoon, and thanks for being with us on today's call covering our second quarter results and business update. On the line with me is Lisa Delfini, who serves as Chief Financial Officer of Trevi. Lisa and I will deliver some prepared comments, and afterward we'll take your questions. Throughout the quarter, we kept moving forward with our clinical development efforts for Haduvio as well as our chronic cough indications. I'd like to give you a quick status report on every one of our programs, starting with our lead program, which targets chronic cough and IPF. IPF is a severe disease that ends lives. Chronic cough together with IPF affects patients on physical, psychological, and social levels, lowering their quality of life. Since no treatments are approved right now for chronic cough, patients urgently need new therapeutic options. On top of that, chronic cough could be a risk factor contributing to how IPF progresses. Ongoing damage to the lungs, tiny tears, and possible inflammation brought about by relentless coughing can cause the disease to worsen and may worsen outcomes for patients; in this next stage of development for our IPF chronic cough program, we intend to run two studies side by side. The first one is a four-arm phase II-B dose-ranging trial examining three active doses of Haduvio along with placebo; we're aiming for a total N of roughly 160 subjects enrolled, with six weeks of dosing. Our plan is to run this study across many countries and sites so that enrollment can be finished promptly. You're probably aware that a great deal of development activity is underway involving antifibrotics in IPF patients; we anticipate that enrollment will be competitive; we believe our trial stands out for patients and investigators, since it's the only chronic cough study in IPF that has previously reported positive data; the protocol for the dose-ranging study is now finalized, and we're currently navigating the various submissions to regulatory authorities. Country selection is also done, and we're in the process of qualifying sites, negotiating budgets, and getting sites ready for this trial to begin. We anticipate launching this trial during the second half of this year, assuming our regulatory interactions get finalized. At the same time, we're making plans for a phase I-B respiratory physiology study. Right now, there's class labeling that carries a generic risk of respiratory depression being caused. That's not something our safety data have shown across the studies we've run so far. Literature exists indicating that mixed agonist-antagonists — the class nalbuphine belongs to — have a ceiling effect when it comes to respiration impact. Even so, because of the pulmonary function found in the IPF population, characterizing Haduvio's effect, if there is one, on respiratory depression among IPF patients matters. Trevi intends to run a phase I-B inpatient study involving IPF patients with differing degrees of disease severity, to figure out whether we observe any clinically significant impacts on respiratory depression; this study will assist in defining the patient population for our pivotal program and, in the end, the label. We've gotten feedback from the FDA regarding the phase I-B trial we're planning, we've locked in a protocol, and we're handling the prep work alongside the 2 sites that will run that study. The IND paperwork is nearly done, and we're looking at kicking this trial off during the back half of this year too. Beyond the work we're doing in IPF cough, a protocol for a phase II trial in refractory chronic cough, or RCC, is now complete as well. Our thinking is that since Haduvio acts both in the brain centrally and in the lungs peripherally, it could potentially deliver treatment across a variety of chronic cough indications, no matter what disease sits underneath; we anticipate this trial will closely resemble the CANAL trial, which used a dose-escalating crossover design, and our plan is to enroll roughly 60 subjects. A great many trials have been run in RCC, yet just one mechanism has achieved a measure of success — the P2X3s, which work peripherally in the lungs from a mechanistic standpoint. Even so, our view is that a meaningful opportunity remains for a mechanism acting both centrally and peripherally that could potentially deliver robust and consistent efficacy in RCC patients who are the hardest to treat, among them those with elevated cough counts, and also in patients sitting below the enriched threshold of 20 coughs per hour that RCC trials presently use. As we put our own RCC study together, we're drawing on what other companies have learned...During the quarter, our phase II IPF cough data and mechanism kept drawing considerable attention at medical conferences, with oral presentations given at the American Thoracic Society meeting and at the American Cough Conference. On top of that, results from the CANAL trial came out in NEJM Evidence. I'd say this reflects how significant the unmet medical need is for these IPF cough patients who are difficult to treat, and how interested the medical community is in our program across cough indications. Prurigo nodularis, or PN, is the other indication where we have ongoing work; right now we're finishing up the data analysis from the 1-year open label extension study tied to PRISM. It's our intention to present those findings at a dermatology conference coming up. We also intend to pursue an end of Phase II meeting with the FDA, and we expect to make that request later this year. Once that meeting happens, we'll figure out the program's next steps. Last of all, we're running a human abuse potential study, something the NDA filing requires. Keep in mind that the parenteral form of nalbuphine is presently unscheduled in the U.S. by the Drug Enforcement Administration, or DEA. What this study aims to do is compare how likable, or how abusable, oral nalbuphine is against an active comparator we've settled on, which for this study is butorphanol. Butorphanol carries a Schedule IV classification. Two parts make up this study, and the goal for the first of them is to profile a range of butorphanol doses and then pick one that works for comparing against oral nalbuphine. Part one is finished, and for part two we've chosen the nalbuphine and butorphanol doses. That data has gone to the FDA so we can hear their feedback. For the second portion, the design is randomized, double-blind, active, and placebo-controlled with five-way crossover, and its purpose is establishing the abuse potential of three oral nalbuphine doses versus the chosen butorphanol dose and placebo. Right now this portion has slipped somewhat because IV butorphanol — the comparator drug here — is in short supply across the country. Our effort was to lock in supply from the sole U.S. supplier, but a tornado recently caused damage at that plant, so before we restart supply discussions, the company needs time to work through that situation. As soon as IV butorphanol is secured and the FDA gives us input on the recommended doses, the final portion of the study will begin. A key point: none of our planned clinical trials have this study on their critical path. To wrap up, our attention is on launching these three chronic cough studies and opening strong sites that will drive solid enrollment. As each study starts, we'll announce it and share further detail on its design and anticipated timelines. Now I'll hand things to Lisa for our financial results. After that, we'll take whatever questions you have.
Lisa Delfini
executiveThanks, Jennifer, and good afternoon to all of you. You can find the complete financial results for the 3 months that ended on June 30th, 2023 in the press release we put out before this call, as well as in our 10-Q, which we filed with the SEC today once the market had closed. During the second quarter of 2023, our net loss came in at $7.1 million, versus a net loss of $8.1 million in the comparable quarter of 2022. R&D expenses reached $5.8 million in the second quarter of 2023, up from $5.1 million in the same quarter of 2022. That rise stemmed mainly from greater consulting and professional fees tied to startup work on the 3 planned chronic cough trials, along with higher personnel-related expenses. G&A expenses came to $2.5 million in the second quarter of 2023, versus $2.7 million in the equivalent period of 2022. That decline resulted from lower market research costs. Other income, net, was $1.2 million in the second quarter of 2023, versus other expense, net, of $0.2 million in the equivalent period of 2022. This shift came mainly from greater interest income driven by larger cash balances and elevated interest rates. As of June 30, 2023, cash, cash equivalents, and marketable securities together amounted to $94.2 million, versus $120.5 million as of December 31, 2022. As I mentioned on the prior quarter's call, we chose during the quarter to fully repay our term loan. The amount paid off was $6.5 million. That loan had been with Silicon Valley Bank, which is now a division of First Citizens Bank. We repaid it in order to release ourselves from restrictions the lender had imposed. Our guidance on cash runway — that we will hold cash, cash equivalents, and marketable securities into 2026 — is still unchanged, and we believe it is sufficient to fund every trial Jennifer just described and leave us with a solid cash runway following the final readout. That wraps up our prepared remarks. I'll now hand the call back to the operator for Q and A.
Annabel Samimy
analystHello, everybody, and thank you for taking my question. I wanted to briefly review the takeaways you obtained from the other RCC studies. You moved through that rather fast, and in what ways could this patient population act differently compared with IPF? You said the trial design would remain identical, so I was hoping to grasp the particular details of that. Thanks.
Jennifer Good
executiveOkay, that's a fair question, Annabel. What we've taken away really centers on the endpoint. That's where the objective cough monitor got locked in, and clearly the counting validation and everything tied to it. The largest argument that emerges, I'd say, is the matter of how much enrichment is appropriate and how much is not, and internally we've had quite a robust discussion about it. The BELLUS study, as you're aware, used what I believe was a three to one enrichment approach centered on greater than 20 coughers. In our IPF cough data and IP, however, no difference showed up tied to cough level; and after going to some of these medical meetings and running our own advisory boards, a substantial unmet need exists for what doctors consider severe coughers, those sitting in the 10 to 19 cough per hour band. To them, that represents severe disease. The BELLUS data, and I've even heard this about the Merck data, effectively applies only to those higher cough counters, and that isn't a large share of the market. Our trial will be stratified, with half the subjects actually drawn from the 10 to 19 coughs per hour group and the greater than 20 coughs per hour group; we're confident doing so given what we observed in IPF cough and how it behaved across the different cough levels. That, I'd say, was the largest argument. Beyond that, the protocol is similar, and the inclusion and exclusion criteria are similar as well.
Annabel Samimy
analystAll right, that's good. So I just want to make sure — you mentioned butorphanol isn't a rate-limiting step for any of the trials, not IPF and not RCC, is that right?
Jennifer Good
executiveThat's right. It just acts as a bottleneck on the way to our ultimate human abuse potential data, yet no, the clinical studies aren't affected at all.
Annabel Samimy
analystOkay, great. Thank you very much.
Jennifer Good
executiveThank you, Annabel.
Serge Belanger
analystHello, and good afternoon. We have a few brief questions for you. I suppose the first one concerns how many locations you plan to use for the phase II-B dose-ranging study. Previously, as I recall, you stated that enrollment for this study, roughly 200 patients, would take around a year. I'm simply wondering whether you're still roughly in that same range, since you noted that enrollment could be competitive. Thank you.
Jennifer Good
executiveYes, those are two solid questions. Regarding how many sites for the II-B, that's still being finalized. We're handling a great deal of the site qualifications, but it will be roughly 60 to 70 sites. That work is in progress. As for the 12-month enrollment, there's one change: at the outset, we believed it would be approximately 200, but once we refined our statistical assumptions, in the end, it will be 160. That's useful; and indeed, we still expect enrollment to take 12 months.
Serge Belanger
analystGreat. Thanks.
Jennifer Good
executiveThank you, Serge and Rohit.
Leland Gershell
analystHello, good afternoon, and I appreciate the update and your willingness to take our questions. I just wanted to inquire about the human abuse potential study. Clearly, you are testing doses that are significantly greater than those being used in your work across IPF, chronic cough, and RCC. I am just curious whether, if you begin to observe some liability at those higher doses—levels beyond what would be considered for the potential indications—that might have an effect on labeling or DEA restrictions. How should we think about what the possible scenarios might be based on those data? Thank you.
Jennifer Good
executiveYes, that is a good question, Leland. I hear this question frequently regarding what constitutes success here, and there is no simple answer, because as you know, the DEA will examine many factors in totality, including our clinical databases and so on. I think generally we will have a low dose of nalbuphine, roughly the marketed dose of nalbuphine, and then a high dose, around which we have completed all the work. It will be approximately 3x the marketed dose. We have already done work characterizing all of those doses. Interestingly, no increase in any type of likability appears as you reach those high doses. It is tolerated, which is interesting, but not surprisingly, the kappa ends up getting swamped, that receptor, and so you get many of those dysphoric side effects that really hit hard when you go up to those high doses. We are not anticipating seeing that. I think if you did, that would certainly factor in, and I think that is somewhat what has made butorphanol a Schedule IV drug. I think the real answer would be that if you saw an increase in likability around nalbuphine as doses became higher, you would compare what that high dose looked like to butorphanol. If they are similar, then you could be discussing a Schedule IV type drug, which, and the conditions we are in, these are serious conditions. Many of these patients are on opioids anyway; we do not see that as impacting the market.
Leland Gershell
analystUnderstood. Alright, with the butorphanol shortage you mentioned, it sounds like this will extend beyond the close of the year. Can you give any indication of when those data might become available — presumably the first half of 2024 — or is there anything you're able to share? Thanks.
Jennifer Good
executiveYes, that's a fair question. We certainly won't make it to the end of the year, since dosing needed to happen in June and July, and that was the issue we were addressing on the previous call. It simply hinges on circumstances. That facility belongs to Pfizer, and it comes down to how things unfold there. We've been talking with them, and honestly they've been very open and cooperative. My hope is that once this situation resolves, perhaps we can bring that work in-house, and we'll continue to keep everyone informed. As of right now, no fresh guidance has been issued, simply because, as you can imagine, this sits largely outside our hands.
Leland Gershell
analystGot it, that makes sense. Okay, I really appreciate you taking my questions.
Jennifer Good
executiveOf course. Thanks, Leland.
Analyst
analystHello, Matt Sharon here, filling in for Tom Smith. To start off, I'd like to know what the gating factors are for kicking off these 3 chronic cough studies? For instance, which one is expected to launch first? I have another question after this.
Jennifer Good
executive... Yes, of course. The main things holding us up are really just about securing approval from regulators. We're essentially set to begin. The protocols have been drafted, sites are being brought under contract, you know, being prepared to start; all that remains is receiving the final green light from the agencies and having everything lined up. My best estimate for the initial study that will be ready is probably the RCC trial.
Analyst
analystUnderstood. What kind of approach are you intending to roll out so you can go head-to-head with the other rival programs in chronic cough IPF?
Jennifer Good
executiveRight. There's just a single other rival program out there in IPF chronic cough. That one is a NeRRe drug, a phase II effort, and that compound failed to succeed in RCC, which is why we don't regard them as a serious rival. From what I understand, their whole study aims to recruit only around 80 patients, roughly, so we don't regard them as a serious rival. To me, the tougher competitive battle is over the IPF patients themselves, since plenty of activity is happening around antifibrotics and IPF. What I believe our edge will come down to is that we're running 1 of the very few cough trials. For those dealing with severe cough, I expect that will come across as intriguing. On top of that, ours is a brief study — six weeks long. As for the antifibrotic trials, many of them involve, you know, commitments lasting one year. When a patient can join a six-week trial and they're severe coughers, that might strike them as an intriguing proposition. And honestly, we're simply standing up enough sites that, you know, we can distribute this work and wrap it up quickly.
Analyst
analystThat tracks. Perhaps a final item from our side. Given that Merck just resubmitted the NDA for the RC, RCC drug, does that shift your thinking at all regarding your approach in RCC? Are you still intending to secure a partner for pushing VO and RCC past phase I-B?
Jennifer Good
executiveThanks, Matt, that's a solid question. My sense is that we intend to handle the development effort ourselves, get a handle on what this asset is worth, and build flexibility into the situation. You're correct that commercializing in RCC is a distinct kind of beast compared with commercializing in a specialty indication such as IPF, though those matters can all be resolved down the road. As you know, a great many parties have interest in this cough area. If we're able to generate strong data, I find it particularly compelling when we can operate across a wider swath of this population of patients with severe cough, which wouldn't need such heavy enrichment. That, to me, would instantly position this asset as best in class. We'll get the development effort done and determine, you know, the optimal way to commercialize it afterward.
Analyst
analystUnderstood—thanks a lot.
Jennifer Good
executiveYes, and thanks to you, Matt.
William Wood
analystHello everyone, William Wood here filling in for Mayank. We appreciate you letting us ask questions. Regarding the butorphanol shortage, after hearing what the FDA had to say, and based on how long that shortage actually lasts, could there be a situation where you have to do part one over again, move forward as planned, or might you be weighing some other alternatives — maybe the worst case?
Jennifer Good
executiveI'd say worst case. The sole situation in which I believe we would need to repeat part one — I suppose it's possible the agency could ask us to examine another dose. We did evaluate several doses in that setting. Should they, for whatever reason, want us to study a different dose, all we'd need to do is give the drug to a small cohort and produce that data. I believe the design we assembled holds up scientifically, though we do want it confirmed prior to conducting an entire likability study. As you suggest, the worst case would involve selecting a different comparator in place of butorphanol, and then securing the agency's blessing that it was a suitable one — pentazocine is probably the most probable alternative. The trouble is, these problems don't simply go away. Every one of these older IV drugs tends to be in limited supply, since essentially a single manufacturer makes them. My hope is we never reach that stage, but should we, we'd likely be discussing with the agency which comparator would make sense instead, which, as I mentioned, came down to a near toss-up between butorphanol and pentazocine back when we made the choice. Either one, in my view, would work well for us, and after that we'd need to redo the dose work.
William Wood
analystRight. No, that's logical. And also, when — I realize ERS is coming up soon, in early September — we're anticipating that the PACIFY low-dose morphine study readout is going to be presented there. In terms of how it could read through to your Nalbuphine ER, how should we be thinking about that data?
Jennifer Good
executiveYeah, we'll have a full team present at ERS, so anybody who's attending, we'd be glad to put you in touch with our group on site. Yeah, I mean, William, this is something you and I have discussed previously. I mean, I will be surprised. This is a morphine trial. Morphine is currently used for cough — low-dose morphine — more so in the U.K., less so here, given all the opioid restrictions. If it doesn't work, I'll be surprised. Dr. Molyneux is the lead investigator on that, and he was in our study too. Excellent investigator. My view is that the read-through is that the mechanism is correct — that opioids are effective in cough. My view is that low-dose morphine will always face challenges. It's a Schedule II opioid. You know, it's generic. Getting IP around that is probably not going to be possible at all. I, I actually believe it confirms the mechanism and, from a commercial standpoint, doesn't compete with what we're doing.
William Wood
analystGot it. Then just one final quick thing. Based on your previous earnings release, or from the 10-Q, it seemed RCC was scheduled for Q3, and now it's shown as the second half. Should we interpret that as a delay, or is it simply a broader way of putting it?
Jennifer Good
executiveIt's really just wording. In our Q, I believe you'll find we continue to reference the third quarter. In certain parts of what I said, I may mention later this year, but that's really just an informal remark.
William Wood
analystUnderstood. Thanks for that. We appreciate you letting us ask our questions.
Jennifer Good
executiveSure. Thanks, William.
Jennifer Good
executiveEveryone, thanks for joining us on today's call. There are a number of conferences coming up that we'll be taking part in, beginning next week with Stifel, and you can find the details in the earnings release we put out today. We hope some of you will be there at those meetings. Thanks.
Operator
operatorThat brings this conference call to a close. We appreciate your participation in today's presentation. You are free to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.